Associated Papers
[Detection of promoter and 3' UTR mutation in A20 gene of a case with T cell lymphoma cell leukemia].
Zhou LL et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi, 2018
[Analysis of DNMT3a mutation in childhood acute myeloid leukemia].
Zhou JF et al.
Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2012
Leukemia-associated mutations in SHIP1 inhibit its enzymatic activity, interaction with the GM-CSF receptor and Grb2, and its ability to inactivate PI3K/AKT signaling.
Brauer H et al.
Cellular Signalling, 2012
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.
McCubrey JA et al.
Oncotarget, 2012
[Association of CD38 gene polymorphism with pathogenesis of chronic myeloid leukemia].
Li J et al.
Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2011
[Analysis of CEBPA mutation in acute myeloid leukemia].
Zhang Y et al.
Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2010
Akt as a therapeutic target in cancer.
Steelman LS et al.
Expert Opinion on Therapeutic Targets, 2008
The investigation of mutation and single nucleotide polymorphism of receptor tyrosine kinases and downstream scaffold molecules in acute myeloid leukemia.
Zhang SJ et al.
Leukemia & Lymphoma, 2006
[Study of mutation and single nucleotide polymorphism of PDGFRbeta and SHIP gene in acute myeloid leukemia].
Zhang SJ et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi, 2006
Select a paper to view details